Journey with AxxessBio:
Stay informed with our latest news, press releases and shared milestones

TEPADINA® (thiotepa) for Haematopoietic Stem Cell Transplantation is now approved in Singapore

AxxessBio is pleased to announce that Health Sciences Authority (HSA) Singapore has granted the registration rights to supply TEPADINA® (thiotepa) 100mg and TEPADINA® (thiotepa) 15mg with the following indications:

  • With or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients
  • When high dose chemotherapy with HPCT support is appropriate for the treatment of breast cancer in adult patients and CNS tumours in paediatric patients

*Please refer to the local package insert for full prescribing information.

Interested in Partnering Up?

At AxxessBio, we are continuously looking for partnerships to bring new innovative therapies for patients all around Asia